BOULDER, COLORADO, December 3, 2012 –Siva Therapeutics has closed an initial angel financing round; this funding, together with a recent $350,000 grant from Breakout Labs, has enabled Siva to expand operations and to undertake a new series of studies on its nanotechnology enabled photothermal therapy. With this financing in place, Siva has hired a Bioengineer who will be leading the new studies, and is moving operations to a 2,400 square foot laboratory and office suite in Flatiron Park east of Boulder.
“We are excited to be starting a new series of studies that will advance SivaRod™ therapy toward the clinic,” said Len Pagliaro, PhD, CEO of Siva, “We now have the personnel and financing to move ahead more quickly.” The new studies will evaluate the use of SivaRods™ as a standalone and combination cancer therapy, and will also allow Siva to advance early stage R&D to determine the next cancer to be targeted by SivaRods™.
About Siva Therapeutics Inc
Siva Therapeutics Inc is an early stage biotechnology company developing a photothermal device cancer therapy which uses heat to irreversibly damage solid tumor tissue. The heat is delivered to tumors by infrared light that is absorbed by gold nanoparticles and re-emitted as heat. The size, shape, and surface chemistry of the particles target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Siva therapy promises to be extremely safe, effective, and competitive in cost relative to surgery, chemotherapy, and radiation for cancer treatment. For more information please visit: www.sivatherapeutics.com.
Media Contact: email@example.com
PDF version of this article: December 03, 2012 – Siva Therapeutics Closes Angel Financing Round, Moves into New Facilities